QATCH Technologies

QATCH Technologies is a privately held instrumentation company focused on the biopharmaceutical development sector. Its core innovation is a sensor-based platform that measures viscosity and injectability using only microliter sample volumes, addressing a critical bottleneck in formulating biologics for subcutaneous delivery. The company appears to be in an early commercial stage, generating revenue through the sale of its benchtop instruments (nanovisQ series) and a viscosity testing service while continuing platform development with its visQ.AI software. Its value proposition centers on accelerating and de-risking drug development by providing formulation scientists with precise, predictive data on manufacturability and patient injectability early in the preclinical process.

Proprietary sensor and AI software platform for micro-volume viscosity measurement and injectability prediction of biopharmaceutical formulations.

QATCH competes in the analytical instrumentation space for biopharma, primarily against traditional rotational rheometer manufacturers like TA Instruments (Waters) and Anton Paar, whose instruments are often bulkier and require larger sample volumes. It also faces potential competition from other startups developing microfluidic or acoustic wave-based viscosity sensors. Its key competitive advantages are its ultra-low sample consumption and its focused software on predicting injectability, a specific formulation bottleneck.